Resistance to anti-HCV protease inhibitors
Date
2011
Authors
Thompson, A.J.
Locarnini, S.A.
Beard, M.R.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Current Opinion in Virology, 2011; 1(6):599-606
Statement of Responsibility
Alexander J Thompson, Stephen A Locarnini, and Michael R Beard
Conference Name
Abstract
The era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges. For the first time, drug resistance has become an issue to consider in the management of HCV. This brief review summarizes the current literature concerning resistance to the HCV NS3 protease inhibitors, both experimental and clinical, and identifies the key questions facing the field.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2011 Elsevier B.V. All rights reserved.